AQP4 holds great potential as a therapeutic target for Alzheimer’s disease, with drug development and lifestyle interventions, such as aerobic exercise and dietary regulation, being promising approaches to restore AQP4 polarity and enhance its metabolic waste (i.e., β-amyloid) clearance capacity [50,51]. Here, AQP4 is linked to early-onset autosomal dominant Alzheimer disease.